Exclusive Summary

• Game-changing adherence via ultra-long acting profile: As a novel oligonucleotide therapeutic, UB665 achieves monthly or even bi-monthly subcutaneous dosing, solving the severe patient compliance bottleneck associated with current weekly GLP-1 peptides.
• First-in-class multi-target mechanism: Combining GLP-1/GIP/GCG/FGF21 targets, it offers a dual mechanism of fat mobilization and profound lipid clearance, perfectly bridging the multi-billion-dollar Obesity and MASH overlapping markets.
• Superior pre-clinical Best-in-class potential: In DIO-MASH mouse models, UB665 outperformed Tirzepatide in weight loss (29.0% vs 24.2%) and liver histology/lipid profiles, alongside staggering monkey data showing 10.5% weight loss and 32% TG reduction from a single dose up to day 28.
• Extremely high global License-out appeal: It provides international pharmas looking to disrupt the GLP-1 peptide red ocean with a strategic 'leapfrog' asset, combining a novel modality (oligonucleotide) with comprehensive metabolic mastery (Obesity + MASH crossover efficacy).

Asset Materials

Contact Us for Full Materials